The design and development of an immunosuppressive drug, mycophenolate mofetil

Allison, A. C.; Eugui, Elsie M.

doi:10.1007/bf00192309

Cited by 137 publications

(90 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gastrointestinal epithelial cells, as well as other cells in the body, are partially dependent on the de novo pathway for growth and replication. 18 The biopsy changes described in our patients were seen with mycophenolate mofetil, an immediate release formulation of MPA. Whether these changes would also be seen with enteric-coated mycophenolate sodium, which delays MPA release until the small intestine, has yet to be investigated.…”

Section: Discussionmentioning

confidence: 83%

Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil

et al. 2009

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 83%

Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil

et al. 2009

View full text Add to dashboard Cite

“…This, the unknown effects of CsA and tacrolimus toxicity over the long term has prompted many investigators to attempt to withdraw CsA after the early posttransplant period [43]. The use of immunosuppressant therapies in novel combinations may permit the use of CsA (or tacrolimus) in much lower dosages than have been used conventionally, while still maintaining adequate immunosuppression and preventing allograft rejection [2]. CsA and tacrolimus are both calcineurin inhibitors; [14, 751 thus, any alternative immunosuppressant, such as mycophenolate mofetil (MMF), must have a different mechanism of action.…”

Section: Csa-and Tacrolimus-sparing Regimensmentioning

confidence: 99%

Neurotoxicity of calcineurin inhibitors: impact and clinical management

Bechstein¹

2000

Transplant Int

475

284

View full text Add to dashboard Cite

Between 10 %-28 % of patients who receive the immunosuppressant cyclosporine (CsA) experience some form of neurotoxic adverse event. Both sensorial motoric functions may be adversely affected, and thus patients present with a wide range of neurological and psychiatrical disorders. Mild symptoms are common and include tremor, neuralgia, and peripheral neuropathy. Severe symptoms affect up to 5 % of patients and include psychoses, hallucinations, blindness, seizures, cerebellar ataxia, motoric weakness, or leukoencephalopathy.

show abstract

“…GI epithelial cells, as well as other cells in the body, are partially dependent on the de novo pathway for growth and replication. 21 This study exposes the wide spectrum of GI pathology in patients with kidney disease. There exists a significant difference in GI complications between patients with endstage renal disease and renal allograft recipients.…”

mentioning

confidence: 99%

Gastrointestinal Complications in Patients with Chronic Kidney Disease—A 5-Year Retrospective Study from a Tertiary Referral Center

et al. 2012

View full text Add to dashboard Cite

Background: Gastrointestinal complications are frequent in patients with renal disease and are responsible for substantial morbidity and mortality among these patients in developing countries. Many times, these patients are subjected to endoscopic evaluation and mucosal biopsies are taken for definitive diagnosis. This study explores the various upper and lower nonneoplastic gastrointestinal complications in patients with chronic kidney disease (CKD) and the role of endoscopic mucosal biopsies in the management of these patients. Methods: Sixty-three patients with CKD, who were referred to endoscopic evaluation and biopsy due to significant gastrointestinal symptoms between January 2007 and December 2011 form the study group. Patients were divided into two groups: group 1 and group 2. Group 1 consisted of patients with CKD stages 1-5 and group 2 consisted of renal allograft recipients. All biopsies were reviewed by an experienced pathologist. Clinical data were collected from patient's medical records. Results: There were 38 patients in group 1 and 25 patients in group 2. Twenty-nine out of 38 patients in group 1 presented with upper gastrointestinal (GI) symptoms and underwent esophagogastroduodenoscopy (OGD) evaluation, which showed erosive gastritis as the most common biopsy finding followed by ulcerative esophagitis and duodenitis. These patients were also found to be susceptible to develop ischemic colitis due to hypotensive episodes during dialysis, which are likely to occur during the initial stages of dialysis. The most frequent symptom in group 2 was chronic diarrhea (13 out of 25 patients) for which a colonoscopic examination was done which revealed various infection and drug-related colitis, mycophenolate mofetil (MMF) being a major culprit. Conclusion: CKD patients with high urea level are prone to develop upper GI symptoms and mostly show erosive gastritis, ulcerative esophagitis, and duodenitis on biopsy. On the contrary, renal allograft recipients mostly develop opportunistic infections and drug-related toxicity in the colon. MMF-related GI toxicity is an underrecognized entity and further prospective studies are required for its better understanding.

show abstract

The design and development of an immunosuppressive drug, mycophenolate mofetil

Cited by 137 publications

References 63 publications

Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil

Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil

Neurotoxicity of calcineurin inhibitors: impact and clinical management

Gastrointestinal Complications in Patients with Chronic Kidney Disease—A 5-Year Retrospective Study from a Tertiary Referral Center

Contact Info

Product

Resources

About